Greenwood Capital Associates’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.4M Buy
58,299
+2,300
+4% +$60.2K 0.14% 132
2026
Q1
$1.57M Buy
55,999
+869
+2% +$23.1K 0.17% 117
2025
Q4
$1.37M Buy
55,130
+2,249
+4% +$56.7K 0.15% 127
2025
Q3
$1.35M Sell
52,881
-741
-1% -$18.3K 0.16% 127
2025
Q2
$1.3M Sell
53,622
-4,446
-8% -$104K 0.16% 119
2025
Q1
$1.47M Buy
58,068
+7,275
+14% +$190K 0.2% 105
2024
Q4
$1.35M Sell
50,793
-106
-0.2% -$2.88K 0.18% 110
2024
Q3
$1.47M Buy
+50,899
New +$1.48M 0.19% 99
2024
Q2
Sell
-8,821
Closed -$245K 251
2024
Q1
$245K Sell
8,821
-176,105
-95% -$4.89M 0.03% 234
2023
Q4
$5.32M Buy
184,926
+11,853
+7% +$358K 0.69% 54
2023
Q3
$5.74M Sell
173,073
-28,430
-14% -$1.01M 0.83% 40
2023
Q2
$7.39M Buy
201,503
+21,148
+12% +$823K 1.04% 32
2023
Q1
$7.36M Sell
180,355
-5,963
-3% -$258K 1.06% 33
2022
Q4
$9.55M Sell
186,318
-35,666
-16% -$1.71M 1.57% 14
2022
Q3
$9.71M Sell
221,984
-24,276
-10% -$1.18M 1.67% 13
2022
Q2
$12.9M Buy
246,260
+245,708
+44,512% +$12.5M 2.07% 9
2022
Q1
$29K Sell
552
-226,192
-100% -$11.7M 0.01% 183
2021
Q4
$13.4M Sell
226,744
-10,413
-4% -$516K 1.9% 10
2021
Q3
$10.2M Buy
237,157
+76,579
+48% +$3.39M 1.57% 15
2021
Q2
$6.29M Buy
160,578
+5,382
+3% +$209K 0.95% 41
2021
Q1
$5.62M Sell
155,196
-61,205
-28% -$2.17M 0.88% 38
2020
Q4
$7.96M Sell
216,401
-102,462
-32% -$3.76M 1.34% 25
2020
Q3
$11.1M Buy
318,863
+12,239
+4% +$429K 2.16% 9
2020
Q2
$9.51M Sell
306,624
-1,814
-0.6% -$61.6K 2.17% 13
2020
Q1
$9.55M Sell
308,438
-7,647
-2% -$261K 2.8% 7
2019
Q4
$11.8M Buy
316,085
+6,553
+2% +$233K 2.48% 7
2019
Q3
$10.6M Buy
309,532
+76,323
+33% +$2.78M 2.57% 7
2019
Q2
$9.59M Buy
233,209
+9,486
+4% +$377K 2.41% 7
2019
Q1
$9.02M Buy
223,723
+4,438
+2% +$178K 2.32% 11
2018
Q4
$9.08M Buy
219,285
+46,631
+27% +$1.94M 2.38% 8
2018
Q3
$7.22M Sell
172,654
-5,220
-3% -$201K 1.57% 20
2018
Q2
$6.12M Buy
177,874
+2,816
+2% +$96.2K 1.41% 27
2018
Q1
$5.89M Buy
175,058
+1,751
+1% +$60.2K 1.44% 21
2017
Q4
$5.96M Sell
173,307
-2,628
-1% -$89.6K 1.39% 19
2017
Q3
$5.96M Sell
175,935
-4,391
-2% -$141K 1.48% 17
2017
Q2
$5.75M Buy
180,326
+7,483
+4% +$236K 1.49% 17
2017
Q1
$5.61M Buy
172,843
+89
+0.1% +$2.81K 1.47% 12
2016
Q4
$5.32M Buy
172,754
+23,952
+16% +$731K 1.5% 15
2016
Q3
$4.78M Sell
148,802
-4,471
-3% -$149K 1.45% 16
2016
Q2
$5.12M Sell
153,273
-2,737
-2% -$87.4K 1.58% 13
2016
Q1
$4.39M Sell
156,010
-1,786
-1% -$51K 1.38% 19
2015
Q4
$4.83M Sell
157,796
-455
-0.3% -$14.3K 1.56% 15
2015
Q3
$4.72M Sell
158,251
-4,754
-3% -$152K 1.67% 15
2015
Q2
$5.18M Sell
163,005
-6,105
-4% -$199K 1.57% 15
2015
Q1
$5.58M Sell
169,110
-2,876
-2% -$91.4K 1.6% 14
2014
Q4
$5.08M Buy
171,986
+1,711
+1% +$49.1K 1.47% 20
2014
Q3
$4.78M Sell
170,275
-84,239
-33% -$2.36M 1.47% 20
2014
Q2
$7.17M Buy
254,514
+106,094
+71% +$3.02M 2.22% 5
2014
Q1
$4.52M Sell
148,420
-8,614
-5% -$257K 1.45% 21
2013
Q4
$4.56M Buy
157,034
+913
+0.6% +$26.6K 1.42% 22
2013
Q3
$4.25M Sell
156,121
-528
-0.3% -$14.4K 1.5% 20
2013
Q2
$4.16M Buy
+156,649
New +$4.33M 1.81% 18

Other funds holding PFE

Greenwood Capital Associates's PFE Position: Q2 2026 in Review

Greenwood Capital Associates increased its Pfizer (PFE) stake by 4.1% in Q2 2026, buying an estimated $60.2K and bringing the position to 58,299 shares worth $1.4M. The position accounts for 0.14% of the portfolio, ranked #132.

Greenwood Capital Associates first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.4M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Greenwood Capital Associates held 58,299 shares of Pfizer worth $1.4M as of Q2 2026.
  • Greenwood Capital Associates bought 2,300 Pfizer shares in Q2 2026, an estimated $60.2K.
  • Pfizer made up 0.14% of Greenwood Capital Associates's portfolio in Q2 2026, its #132 holding.
  • Greenwood Capital Associates first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Greenwood Capital Associates's Pfizer position peaked at $13.4M in Q4 2021.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.